Stay updated with breaking news from Special Topix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A survey of gastroenterologists, dermatologists, and rheumatologists found Amjevita had the most recognition, followed by Cyltezo, the only interchangeable biosimilar on the US market.
/PRNewswire/ -- Amgen launched the first U.S. adalimumab biosimilar, Amjevita, in January 2023. Yet according to the latest findings from Spherix Global...
/PRNewswire/ -- AbbVie's Humira (adalimumab) is the world's best selling drug, but the entry of biosimilar challengers, with Amgen's Amjevita being the first...
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and...
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and...